From: Dietary intake of trans fatty acids and breast cancer risk in 9 European countries
ER− and PR− | ER+ and PR+ | Pheterogeneity | ||
---|---|---|---|---|
n = 1259 HR (95% CI) | n = 4830 HR (95% CI) | |||
Total industrial trans fatty acidsa | Q1 | 1 (reference) | 1 (reference) | |
Q2 | 0.99 (0.84–1.18) | 1.13 (1.04–1.23) | ||
Q3 | 1.02 (0.85–1.22) | 1.18 (1.07–1.29) | ||
Q4 | 1.08 (0.87–1.33) | 1.14 (1.02–1.28) | ||
P trend | 0.48 | 0.009 | 0.55 | |
Elaidic acid | Q1 | 1 (reference) | 1 (reference) | |
Q2 | 0.99 (0.83–1.17) | 1.12 (1.03–1.22) | ||
Q3 | 1.01 (0.84–1.21) | 1.19 (1.08–1.31) | ||
Q4 | 1.08 (0.87–1.34) | 1.14 (1.01–1.27) | ||
P trend | 0.49 | 0.007 | 0.52 | |
Total ruminant trans fatty acidsb | Q1 | 1 (reference) | 1 (reference) | |
Q2 | 1.08 (0.89–1.32) | 1.02 (0.92–1.13) | ||
Q3 | 1.13 (0.92–1.39) | 1.01 (0.91–1.12) | ||
Q4 | 1.07 (0.85–1.34) | 1.11 (0.99–1.25) | ||
P trend | 0.63 | 0.055 | 0.64 | |
Palmitelaidic acid | Q1 | 1 (reference) | 1 (reference) | |
Q2 | 0.91 (0.76–1.09) | 1.01 (0.92–1.11) | ||
Q3 | 1.05 (0.86–1.28) | 1.07 (0.96–1.18) | ||
Q4 | 1.03 (0.84–1.26) | 1.09 (0.98–1.21) | ||
P trend | 0.46 | 0.07 | 0.84 | |
Conjugated linoleic acid | Q1 | 1 (reference) | 1 (reference) | |
Q2 | 1.09 (0.90–1.33) | 0.99 (0.89–1.09) | ||
Q3 | 1.11 (0.90–1.38) | 1.01 (0.90–1.12) | ||
Q4 | 1.12 (0.89–1.41) | 1.10 (0.98–1.24) | ||
P trend | 0.38 | 0.056 | 0.90 | |
Vaccenic acid | Q1 | 1 (reference) | 1 (reference) | |
Q2 | 0.98 (0.76–1.26) | 1.08 (0.94–1.23) | ||
Q3 | 0.90 (0.71–1.14) | 1.14 (1.01–1.29) | ||
Q4 | 0.92 (0.72–1.17) | 1.09 (0.96–1.23) | ||
P trend | 0.39 | 0.26 | 0.20 |